S&P also assigned a “BBB-” long-term rating to the health system’s $915 million of series 2017 fixed-rate bonds.
“The rating action primarily reflects our view of MetroHealth’s large capital project and the related increased pro forma debt levels from the series 2017 issuance coupled with an existing financial profile that we consider somewhat light,” said S&P analyst Suzie Desai.
The outlook is stable, reflecting S&P Global Ratings’ opinion the health system will return to operating stability through interim 2017 with the implementation of several key initiatives.
More articles on healthcare finance:
9 recent hospital outlook and credit rating actions
Moody’s affirms ‘A2’ rating on Greater Baltimore Medical Center’s bonds
Letter to the editor: Cigarette tax is key for our community
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
